MCID: PRN009
MIFTS: 47

Paranoid Schizophrenia

Categories: Mental diseases

Aliases & Classifications for Paranoid Schizophrenia

MalaCards integrated aliases for Paranoid Schizophrenia:

Name: Paranoid Schizophrenia 12 55 15 72 33
Chronic Paranoid Schizophrenia 12 72
Paranoid Type Schizophrenia Subchronic State 12
Paranoid Type Schizophrenia 12
Paraphrenic Schizophrenia 12
Schizophrenia, Paranoid 44
Paraphrenia - Late 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1229
MeSH 44 D012563
NCIt 50 C35006
SNOMED-CT 68 31658008 64905009
ICD10 33 F20.0
UMLS 72 C0036349 C0270398

Summaries for Paranoid Schizophrenia

Disease Ontology : 12 A schizophrenia characterized by delusions or auditory hallucinations of persecution or being plotted against without thought disorder, disorganized behavior, or affective flattening.

MalaCards based summary : Paranoid Schizophrenia, also known as chronic paranoid schizophrenia, is related to avoidant personality disorder and early-onset schizophrenia. An important gene associated with Paranoid Schizophrenia is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Calcium signaling pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Cycloserine and Ziprasidone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 75 Paranoid schizophrenia is the most common type of schizophrenia. Schizophrenia is defined as "a chronic... more...

Related Diseases for Paranoid Schizophrenia

Diseases related to Paranoid Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 30.8 SLC6A4 MAOA
2 early-onset schizophrenia 30.6 HTR2A BDNF
3 tardive dyskinesia 30.6 HTR2A COMT
4 alexithymia 30.2 SLC6A4 COMT
5 bipolar disorder 30.1 SLC6A4 HTR2A COMT BDNF
6 traumatic brain injury 29.9 S100B COMT BDNF
7 brain injury 29.9 S100B COMT BDNF
8 schizoaffective disorder 29.9 SLC6A4 HTR2A COMT BDNF
9 personality disorder 29.8 SLC6A4 MAOA HTR2A COMT BDNF
10 depression 29.7 TPH2 SLC6A4 MAOA HTR2A BDNF
11 endogenous depression 29.6 SLC6A4 MAOA HTR2A BDNF
12 anxiety 29.5 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
13 autism spectrum disorder 29.5 TPH2 SLC6A4 HTR2A BDNF
14 alcohol dependence 29.4 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
15 psychotic disorder 29.3 SLC6A4 S100B HTR2A COMT BDNF
16 post-traumatic stress disorder 29.3 SLC6A4 MAOA HTR2A COMT BDNF
17 mood disorder 29.1 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
18 mental depression 28.9 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
19 obsessive-compulsive disorder 28.8 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
20 major depressive disorder 28.8 TPH2 SLC6A4 MAOA HTR2A COMT BDNF
21 schizophrenia 28.2 TPH2 SLC6A4 MIAT MAOA HTR2A DRD5
22 substance abuse 28.1 SLC6A4 MIAT MAOA DRD5 COMT BDNF
23 phobia, specific 10.5 MAOA COMT
24 major affective disorder 8 10.3
25 major affective disorder 9 10.3
26 dystonia 1, torsion, autosomal dominant 10.3 MAOA COMT
27 heroin dependence 10.3 MIAT BDNF
28 delusional disorder 10.3
29 subacute delirium 10.3
30 social phobia 10.2 SLC6A4 MAOA
31 schizophrenia 1 10.2
32 schizophrenia 5 10.2
33 psychosexual disorder 10.2 SLC6A4 HTR2A
34 kleptomania 10.2 SLC6A4 MAOA
35 alcoholic psychosis 10.2 SLC6A4 HTR2A
36 periodic limb movement disorder 10.2 SLC6A4 HTR2A
37 opioid addiction 10.2 COMT CCKAR
38 autism 10.1
39 ataxia and polyneuropathy, adult-onset 10.1
40 schizophrenia 3 10.1
41 schizophrenia 9 10.1
42 schizophrenia 15 10.1
43 physical disorder 10.1
44 hypogonadotropic hypogonadism 10.1
45 factitious disorder 10.1
46 mutism 10.1
47 neurotic disorder 10.1
48 severe combined immunodeficiency 10.1
49 capgras syndrome 10.1
50 pathologic nystagmus 10.1

Comorbidity relations with Paranoid Schizophrenia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Alzheimer Disease
Deficiency Anemia Delusional Disorder
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Personality Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder
Tardive Dyskinesia

Graphical network of the top 20 diseases related to Paranoid Schizophrenia:



Diseases related to Paranoid Schizophrenia

Symptoms & Phenotypes for Paranoid Schizophrenia

MGI Mouse Phenotypes related to Paranoid Schizophrenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 BDNF CCKAR COMT DRD5 HTR2A MAOA
2 endocrine/exocrine gland MP:0005379 9.43 BDNF CCKAR COMT DRD5 HTR2A SLC6A4
3 taste/olfaction MP:0005394 8.8 BDNF CCKAR TPH2

Drugs & Therapeutics for Paranoid Schizophrenia

Drugs for Paranoid Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cycloserine Approved Phase 4 68-41-7 6234 401
2
Ziprasidone Approved Phase 4 146939-27-7 60854
3
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
4 Serotonin Antagonists Phase 4
5 Serotonin Agents Phase 4
6 Dopamine Antagonists Phase 4
7 Renal Agents Phase 4
8 Anti-Bacterial Agents Phase 4
9 Antibiotics, Antitubercular Phase 4
10 Antitubercular Agents Phase 4
11 Anti-Infective Agents, Urinary Phase 4
12 Anti-Infective Agents Phase 4
13 Antimetabolites Phase 4
14 Antidepressive Agents Phase 4
15 S 20098 Phase 4
16 Hypnotics and Sedatives Phase 4
17 Central Nervous System Depressants Phase 4
18 Tranquilizing Agents Phase 4
19 Psychotropic Drugs Phase 4
20
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
21
Asenapine Approved Phase 3 65576-45-6, 85650-56-2 3001386
22
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
23
Amisulpride Approved, Investigational Phase 2 53583-79-2, 71675-85-9 2159
24
Olanzapine Approved, Investigational Phase 2 132539-06-1 4585
25
Aripiprazole Approved, Investigational Phase 2 129722-12-9 60795
26 Quetiapine Fumarate Phase 2 111974-72-2
27 Epidiolex Phase 2
28 Anticonvulsants Phase 2
29
Oxytocin Approved, Vet_approved 50-56-6 439302 53477758
30
Dopamine Approved 51-61-6, 62-31-7 681
31 Raclopride Investigational 84225-95-6
32 Oxytocics
33 Serotonin Uptake Inhibitors
34 Sympathomimetics
35 Gastrointestinal Agents
36 Cardiotonic Agents
37 Antiemetics
38 Protective Agents
39 Neurotransmitter Agents
40 Dopamine Agents
41 Antipsychotic Agents
42 Parasympatholytics
43 Cholinergic Agents
44 Cholinergic Antagonists
45 Peripheral Nervous System Agents
46 Muscarinic Antagonists
47 Neurotransmitter Uptake Inhibitors
48 Antiparkinson Agents
49 Dopamine Uptake Inhibitors
50
Benztropine 86-13-5 6832

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia Completed NCT00742079 Phase 4 D-cycloserine
2 Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH) Completed NCT01822418 Phase 4 agomelatine
3 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Completed NCT01981759 Phase 4 D-Cycloserine
4 An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis Completed NCT00644800 Phase 4 Ziprasidone
5 A Double-blind Randomized Placebo-controlled Trial of Adjuvant Therapy With Minocycline for Schizophrenia Completed NCT01809158 Phase 4 minocycline;placebo
6 Research Into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial Recruiting NCT03559426 Phase 4 Antipsychotic Reduction;Antipsychotic Maintenance
7 Phase 3 Randomized Controlled Trial of Cognitive Behavioural Therapy for Patients With Schizophrenia Unknown status NCT00300651 Phase 3
8 A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia Completed NCT01190267 Phase 3 asenapine
9 An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia Completed NCT01190254 Phase 3 asenapine 2.5 mg;asenapine 5.0 mg;placebo
10 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
11 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia Completed NCT00482430 Phase 2 MK0557;Comparator: Placebo (unspecified)
12 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia Completed NCT00506077 Phase 2 MK0249;Comparator: Placebo (unspecified)
13 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial Completed NCT01176721 Phase 2
14 A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia Completed NCT00103727 Phase 2 Talnetant
15 The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia Completed NCT02408198 Phase 2
16 Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment Recruiting NCT02926859 Phase 2 Cannabidiol as add-on;Placebo as add-on
17 Comparison of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia With Standard Treatment: Effects on Psychological Parameters and Rehospitalisation Active, not recruiting NCT02787122 Phase 2
18 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone Unknown status NCT00563017 Long-acting Risperidone microspheres injection
19 Integrated Care in Patients With a Psychotic Disorder Fulfilling Definition of Severe Mental Illness (ACCESS-II Study) Unknown status NCT01888627
20 Psychoeducation in Patients With Schizophrenia: Neuropsychological Performance and Cognitive Training as Determinants of Outcome Unknown status NCT00646256
21 Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus Completed NCT00222807
22 Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP) Completed NCT01216891
23 Acceptance and Commitment Therapy for Delusions Completed NCT00657631
24 Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia Completed NCT01028677 intranasal spray with oxytocin
25 The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study. Completed NCT00716755 Risperidone/Olanzapine and PET scans
26 The Momentum Trial: The Efficacy of Using a Smartphone Application to Support Shared Decision Making Through Patient Activation in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings Recruiting NCT03554655
27 Individual Placement and Support (IPS) Enhanced With Cognitive Remediation and Social Skills Training in Denmark: a Randomized Controlled Trial Active, not recruiting NCT01722344
28 Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Non-interventional Study Terminated NCT00617214
29 Anticholinergic Burden in Schizophrenia Terminated NCT00715377 Benztropine

Search NIH Clinical Center for Paranoid Schizophrenia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Chlorprothixene

Cochrane evidence based reviews: schizophrenia, paranoid

Genetic Tests for Paranoid Schizophrenia

Anatomical Context for Paranoid Schizophrenia

MalaCards organs/tissues related to Paranoid Schizophrenia:

41
Brain, Testes, Eye, Cortex, Liver, Thyroid, Temporal Lobe

Publications for Paranoid Schizophrenia

Articles related to Paranoid Schizophrenia:

(show top 50) (show all 1309)
# Title Authors PMID Year
1
Evidence of epistasis between the catechol-O-methyltransferase and aldehyde dehydrogenase 3B1 genes in paranoid schizophrenia. 9 38
19159868 2009
2
[The phenomenology of delusions of poisoning in persons with paranoid schizophrenia]. 38
31390658 2019
3
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. 38
31317083 2019
4
A coin crisis: a case report of pica with minireview. 38
31273687 2019
5
Fred J. Frese III (1940-2018). 38
31305107 2019
6
Paranoid schizophrenia and methamphetamine-induced paranoia are both characterized by a similar LINE-1 partial methylation profile, which is more pronounced in paranoid schizophrenia. 38
30826260 2019
7
Facial Emotion Recognition and Persecutory Ideation in Paranoid Schizophrenia. 38
31092137 2019
8
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection. 38
30747749 2019
9
The Genealogy of Dementia Praecox I: Signs and Symptoms of Delusional Psychoses From 1880 to 1900. 38
29165678 2019
10
A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. 38
30154027 2019
11
Psychoeducational therapy with families of paranoid schizophrenia patients. 38
30745183 2019
12
The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia. 38
30616121 2019
13
Antisocial Personality Traits as a Risk Factor of Violence between Individuals with Mental Disorders. 38
30894931 2019
14
Long non-coding RNA MIAT competitively binds miR-150-5p to regulate ZEB1 expression in osteosarcoma. 38
30655889 2019
15
[Electroconvulsive therapy in treatment of resistant schizophrenia: biological markers of efficacy and safety]. 38
31089103 2019
16
[The use of videooculography in schizophrenia]. 38
31089093 2019
17
Leukocytoclastic vasculitis secondary to clozapine. 38
30745661 2019
18
Elevated brain-derived neurotrophic factor (BDNF) serum levels in an acute episode of schizophrenia in polish women: Correlation with clinical and metabolic parameters. 38
30472511 2019
19
[The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy]. 38
31156221 2019
20
Maternal Infanticide and Filicide in a Psychiatric Custodial Institution in Hong Kong. 38
30563951 2018
21
Adherence, insight and disability in paranoid schizophrenia. 38
30278408 2018
22
Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis: A case report. 38
30558060 2018
23
Unusual high blood glucose in ketoacidosis as first presentation of type 1 diabetes mellitus 38
30306778 2018
24
Potentially fatal outcomes associated with clozapine. 38
29503232 2018
25
In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. 38
30098383 2018
26
Premorbid Adjustment in Predicting Symptom Severity and Social Cognitive Deficits in Schizophrenia. 38
30146494 2018
27
Psychosocial roots of paranoid ideation: The role of childhood experiences, social comparison, submission, and shame. 38
29744971 2018
28
Comparative study of aggression - Dangerousness on patients with paranoid schizophrenia: Focus on demographic data, PANSS, drug use and aggressiveness. 38
30217324 2018
29
On the issue of choosing psychodiagnostic methods of measuring and scoring of cognitive deficit in case of schizophrenia. 38
29464816 2018
30
Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. 38
29790237 2018
31
A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. 38
29898284 2018
32
Chronotropic incompetence of the heart is associated with exercise intolerance in patients with schizophrenia. 38
29526454 2018
33
Therapeutic Particularities with Depot Medications in Schizophrenia. 38
30647956 2018
34
Association Studies of HSPA1A and HSPA1L Gene Polymorphisms With Schizophrenia. 38
30342847 2018
35
Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders? 38
29872020 2018
36
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. 38
29401155 2018
37
Brain and Behavior: Commentary on Two Cases Involving the Effect of Structural Brain Lesions on Psychiatric Disorders. 38
30015791 2018
38
Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia. 38
29363876 2018
39
Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. 38
28951142 2018
40
The difficulties of secondary prophylaxis of cervical cancer in women suffering from paranoid schizophrenia - a case study. 38
29975365 2018
41
Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study. 38
29141100 2018
42
Demographic and clinical features related to perceived discrimination in schizophrenia. 38
28939391 2018
43
Schizophrenia and sense of coherence. 38
29975362 2018
44
Instrumental Activities of Daily Living Dysfunction among People with Schizophrenia. 38
29962569 2018
45
Demographic and Clinical Correlates of Social Cognition in Schizophrenia: Observation from India. 38
29962571 2018
46
Altered corticostriatal pathway in first-episode paranoid schizophrenia: Resting-state functional and causal connectivity analyses. 38
29122402 2018
47
Transdiagnostic deviant facial recognition for implicit negative emotion in autism and schizophrenia. 38
29275843 2018
48
ROS-Induced DNA Damage Associates with Abundance of Mitochondrial DNA in White Blood Cells of the Untreated Schizophrenic Patients. 38
29682166 2018
49
Interstitial deletion within 7q31.1q31.3 in a woman with mild intellectual disability and schizophrenia. 38
30013349 2018
50
Introducing system of psychotherapeutic interventions for family caregivers of patients with endogenous mental disorders. 38
30176626 2018

Variations for Paranoid Schizophrenia

Expression for Paranoid Schizophrenia

Search GEO for disease gene expression data for Paranoid Schizophrenia.

Pathways for Paranoid Schizophrenia

GO Terms for Paranoid Schizophrenia

Cellular components related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of postsynaptic membrane GO:0099055 8.62 SLC6A4 HTR2A

Biological processes related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of phospholipase C activity GO:0007202 9.32 HTR2A BDNF
2 neurotransmitter catabolic process GO:0042135 9.26 MAOA COMT
3 catecholamine metabolic process GO:0006584 9.16 MAOA COMT
4 dopamine catabolic process GO:0042420 8.96 MAOA COMT
5 memory GO:0007613 8.92 SLC6A4 S100B HTR2A BDNF

Molecular functions related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein alpha-subunit binding GO:0001965 8.96 HTR2A DRD5
2 serotonin binding GO:0051378 8.62 SLC6A4 HTR2A

Sources for Paranoid Schizophrenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....